Literature DB >> 12921601

[Clinical features of 96 patients with severe acute respiratory syndrome from a hospital outbreak].

Wei Wu1, Jing-feng Wang, Pin-ming Liu, Wei-xian Chen, Song-mei Yin, Shan-ping Jiang, Li Yan, Jun Zhan, Xi-long Chen, Zi-tong Huang, Jian-xing Xu, Jian-guo Li, Li-ping Ma, Hong-zhang Huang.   

Abstract

OBJECTIVE: To describe a hospital outbreak of severe acute respiratory syndrome (SARS) and summarize the clinical features and therapeutic approaches.
METHODS: Clinical data in this cohort were collected prospectively as they were identified.
RESULTS: The outbreak started with a SARS patient from the community on 30 January 2003, followed by a total of 96 people [76 women and 20 men; mean age (29.5 +/- 10.3) years; 93.8% of whom were health care workers] infected in a short period of time after their exposure to this source patient. The incubation period ranged from 1 to 20 days, with a mean of (5.9 +/- 3.5) days. The initial temperature was (38.3 +/- 0.6) degrees C, while the highest was (39.2 +/- 0.6) degrees C (P < 0.001), with a mean fever duration of (9.0 +/- 4.2) days. Other common symptoms included fatigue, cough, mild sputum production, chills, headache, general malaise and myalgia. The radiographic changes were predominantly bilateral and in the middle or lower lung zones. Leukopenia was observed in 67.7% of this cohort. The mean lowest oxygen saturation was (94.8 +/- 3.1)% with supplementary oxygen through a nasal cannula. 68.8% of the patients were treated with methylprednisolone for a mean period l of (4.9 +/- 2.4) days. The initial dose was (67.3 +/- 28.2) mg/d and the maximal dose was (82.4 +/- 30.5) mg/d. Ninety-five patients (99.0%) had a complete clinical recovery, and 1 patient died of progressive acute respiratory distress syndrome. The mean hospitalized duration was (17.2 +/- 8.0) days.
CONCLUSION: SARS appears to be highly contagious and potentially lethal among health care workers, characterized by acute onset and rapid progression. Corticosteroids, antibiotics, human gamma-globulin, interferon-alpha, and antiviral drugs, although used empirically, might be of some benefits in shortening the clinical course.

Entities:  

Mesh:

Year:  2003        PMID: 12921601

Source DB:  PubMed          Journal:  Zhonghua Nei Ke Za Zhi        ISSN: 0578-1426


  6 in total

Review 1.  Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.

Authors:  Kiarash Saleki; Shakila Yaribash; Mohammad Banazadeh; Ehsan Hajihosseinlou; Mahdi Gouravani; Amene Saghazadeh; Nima Rezaei
Journal:  Eur J Pharmacol       Date:  2021-06-12       Impact factor: 4.432

Review 2.  SARS: systematic review of treatment effects.

Authors:  Lauren J Stockman; Richard Bellamy; Paul Garner
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

Review 3.  A review of treatment modalities for Middle East Respiratory Syndrome.

Authors:  Yin Mo; Dale Fisher
Journal:  J Antimicrob Chemother       Date:  2016-09-01       Impact factor: 5.790

4.  Effectiveness of intravenous immunoglobulin for children with severe COVID-19: a rapid review.

Authors:  Jingyi Zhang; Yinmei Yang; Nan Yang; Yanfang Ma; Qi Zhou; Weiguo Li; Xia Wang; Liping Huang; Xufei Luo; Toshio Fukuoka; Hyeong Sik Ahn; Myeong Soo Lee; Zhengxiu Luo; Yaolong Chen; Enmei Liu; Kehu Yang; Zhou Fu
Journal:  Ann Transl Med       Date:  2020-05

Review 5.  Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses.

Authors:  Zeinab Abdelrahman; Mengyuan Li; Xiaosheng Wang
Journal:  Front Immunol       Date:  2020-09-11       Impact factor: 7.561

Review 6.  Pharmacological treatments of COVID-19.

Authors:  Adeleh Sahebnasagh; Razieh Avan; Fatemeh Saghafi; Mojataba Mojtahedzadeh; Afsaneh Sadremomtaz; Omid Arasteh; Asal Tanzifi; Fatemeh Faramarzi; Reza Negarandeh; Mohammadreza Safdari; Masoud Khataminia; Hassan Rezai Ghaleno; Solomon Habtemariam; Amirhosein Khoshi
Journal:  Pharmacol Rep       Date:  2020-08-20       Impact factor: 3.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.